Abstract
The endocannabinoid system, including endogenous ligands (‘endocannabinoids’ ECs), their receptors, synthesizing and degrading enzymes, as well as transporter molecules, has been detected from the earliest stages of embryonic development and throughout pre- and postnatal development. ECs are bioactive lipids, which comprise amides, esters and ethers of long chain polyunsaturated fatty acids. Anandamide (N-arachidonoylethanolamine; AEA) and 2- arachidonoylglycerol (2-AG) are the best studied ECs, and act as agonists of cannabinoid receptors. Thus, AEA and 2-AG mimic several pharmacological effects of the exogenous cannabinoid delta9-tetrahydrocannabinol (Δ9-THC), the psychoactive principle of cannabis sativa preparations like hashish and marijuana. Recently, however, several lines of evidence have suggested that the EC system may play an important role in early neuronal development as well as a widespread role in neurodegeneration disorders. Many of the effects of cannabinoids and ECs are mediated by two G proteincoupled receptors (GPCRs), CB1 and CB2, although additional receptors may be implicated. Both CB1 and CB2 couple primarily to inhibitory G proteins and are subject to the same pharmacological influences as other GPCRs. This new system is briefly presented in this review, in order to put in a better perspective the role of the EC pathway from neurodevelopment to neurodegenerative disorders, like Alzheimers disease, Parkinsons disease, Huntingtons disease, and multiple sclerosis. In addition, the potential exploitation of antagonists of CB1 receptors, or of inhibitors of EC metabolism, as next-generation therapeutics is discussed.
Keywords: Neurodevelopment, endocannabinoids, CNS, synaptic plasticity, neurodegeneration, CB1 receptors, therapy
Mini-Reviews in Medicinal Chemistry
Title: Endocannabinoid System: Emerging Role from Neurodevelopment to Neurodegeneration
Volume: 9 Issue: 4
Author(s): Balapal S. Basavarajappa, Ralph A. Nixon and Ottavio Arancio
Affiliation:
Keywords: Neurodevelopment, endocannabinoids, CNS, synaptic plasticity, neurodegeneration, CB1 receptors, therapy
Abstract: The endocannabinoid system, including endogenous ligands (‘endocannabinoids’ ECs), their receptors, synthesizing and degrading enzymes, as well as transporter molecules, has been detected from the earliest stages of embryonic development and throughout pre- and postnatal development. ECs are bioactive lipids, which comprise amides, esters and ethers of long chain polyunsaturated fatty acids. Anandamide (N-arachidonoylethanolamine; AEA) and 2- arachidonoylglycerol (2-AG) are the best studied ECs, and act as agonists of cannabinoid receptors. Thus, AEA and 2-AG mimic several pharmacological effects of the exogenous cannabinoid delta9-tetrahydrocannabinol (Δ9-THC), the psychoactive principle of cannabis sativa preparations like hashish and marijuana. Recently, however, several lines of evidence have suggested that the EC system may play an important role in early neuronal development as well as a widespread role in neurodegeneration disorders. Many of the effects of cannabinoids and ECs are mediated by two G proteincoupled receptors (GPCRs), CB1 and CB2, although additional receptors may be implicated. Both CB1 and CB2 couple primarily to inhibitory G proteins and are subject to the same pharmacological influences as other GPCRs. This new system is briefly presented in this review, in order to put in a better perspective the role of the EC pathway from neurodevelopment to neurodegenerative disorders, like Alzheimers disease, Parkinsons disease, Huntingtons disease, and multiple sclerosis. In addition, the potential exploitation of antagonists of CB1 receptors, or of inhibitors of EC metabolism, as next-generation therapeutics is discussed.
Export Options
About this article
Cite this article as:
Basavarajappa S. Balapal, Nixon A. Ralph and Arancio Ottavio, Endocannabinoid System: Emerging Role from Neurodevelopment to Neurodegeneration, Mini-Reviews in Medicinal Chemistry 2009; 9 (4) . https://dx.doi.org/10.2174/138955709787847921
DOI https://dx.doi.org/10.2174/138955709787847921 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cutting-edge Patents in Alzheimers Disease Drug Discovery: Anticipation of Potential Future Treatments
Recent Patents on CNS Drug Discovery (Discontinued) Environmental Toxicants as Extrinsic Epigenetic Factors for Parkinsonism: Studies Employing Transgenic C. elegans Model
CNS & Neurological Disorders - Drug Targets Silver and Other Metals in the Treatment of Gastrointestinal Diseases
Current Medicinal Chemistry Parkinson’s Disease and Alpha-Synucleinopathies: from Arising Pathways to Therapeutic Challenge
Central Nervous System Agents in Medicinal Chemistry Editorial: New Avenues and Therapeutic Strategies for the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Elevated Homocysteine Levels in Parkinsons Disease: Is there Anything Besides L-Dopa Treatment?
Current Medicinal Chemistry The Endocannabinoid System and Multiple Sclerosis
Current Pharmaceutical Design Mechanism(s) Involved in Opioid Drug Abuse Modulation of HAND
Current HIV Research Pharmacological Benefits of Active Components of Natural Products Against Traumatic Brain Injury - A Review
Current Pharmacogenomics and Personalized Medicine GSK3 Inhibitors and Disease
Mini-Reviews in Medicinal Chemistry Past, Present and Future Therapeutics for Cerebellar Ataxias
Current Neuropharmacology Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review of SIRTUIN Activators as Potential Immunomodulators and their Influences on other Dysfunctions
Endocrine, Metabolic & Immune Disorders - Drug Targets Molecular Biomarkers for Amyotrophic Lateral Sclerosis
Current Bioinformatics Diversity and Variability of the Effects of Nicotine on Different Cortical Regions of the Brain. Therapeutic and Toxicological Implications
Central Nervous System Agents in Medicinal Chemistry Oxidative Stress, Pro-Inflammatory Cytokines, and Antioxidants Regulate Expression Levels of MicroRNAs in Parkinson’s Disease
Current Aging Science Differential Susceptibility of Naive and Differentiated PC-12 Cells to Methylglyoxal-Induced Apoptosis: Influence of Cellular Redox
Current Neurovascular Research Conformational Diseases and ER Stress-Mediated Cell Death: Apoptotic Cell Death and Autophagic Cell Death
Current Molecular Medicine Benefits of Caloric Restriction on Brain Aging and Related Pathological States: Understanding Mechanisms to Devise Novel Therapies
Current Medicinal Chemistry Brain: The Potential Diagnostic and Therapeutic Target for Glaucoma
CNS & Neurological Disorders - Drug Targets